{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-23-006962","form_type":"8-K","ticker":"ODYY","cik":"0001626644","company_name":"Odyssey Health, Inc.","filed_at":"2023-10-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.831227+00:00","generated_at":"2026-06-10T04:00:49.403219+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Odyssey Health sells neurological drug pipeline to Oragenics for $1M and 8M preferred shares","bullets":["Oragenics to acquire Odyssey's assets including concussion drug ONP-002 and NPC candidate; cash payment of $1M and 8M Series F Preferred Shares.","Transaction expected to close Q4 2023, subject to shareholder approvals and other conditions, including Oragenics having ≥$5M cash at close.","ONP-002 completed Phase 1 trial; Phase 2 preparation underway; animal studies show reduced swelling, inflammation, oxidative stress.","Odyssey management members intend to join Oragenics post-close to continue development.","Odyssey retains other assets and operations; Oragenics expands into neurological therapeutics via intranasal delivery."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-23-006962","json":"https://secwatch.observer/filing/0001683168-23-006962.json","markdown":"https://secwatch.observer/filing/0001683168-23-006962.md","text":"https://secwatch.observer/filing/0001683168-23-006962.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1626644/000168316823006962/0001683168-23-006962-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1626644/000168316823006962/odyssey_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T04:00:49.403219+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"449bf4937a07decea49b49af83555ea96e77ee4c","claim":"Odyssey Health, Inc. entered into Asset Purchase Agreement with Oragenics, Inc. valued at $1,000,000 in cash and 8,000,000 shares of convertible Series F Preferred Stock (effective 2023-10-04).","evidence_excerpt":"On October 4, 2023, Odyssey Health, Inc. (f/k/a Odyssey Group International, Inc., a Nevada corporation (“ Odyssey ” the “ Company ”) entered into an Asset Purchase Agreement (the “ Purchase Agreement ”) with Oragenics, Inc. (“ Oragenics ” the “ Purchaser ”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1626644/000168316823006962/0001683168-23-006962-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"asset purchase"},{"label":"Counterparty","value":"Oragenics, Inc."},{"label":"Value","value":"$1,000,000 in cash and 8,000,000 shares of convertible Series F Preferred Stock"},{"label":"Effective","value":"2023-10-04"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}